Decision Resources Group to Bring its One-Day Oncology Seminar to San Francisco

January 23, 2012

Geared Toward Pharmaceutical and Biotech Executives, This One-Day Event Will Address Oncology Drug Market Drivers, Challenges and OpportunitiesRead More

Decision Resources Group Analysts Will Examine Oncology Market Drivers, Hurdles and Opportunities at Boston Seminar

September 7, 2011

One Day Seminar to be Held on September 22, 2011
Read More

John Ho Named President of Decision Resources Group Consulting

August 9, 2011

Former Charles River Laboratories Senior Executive Will be Responsible for Leveraging the Company’s Significant Intellectual Capital
Read More

Manhattan Research data quoted in Medical Marketing & Media

February 1, 2012

Patient Education: Vying for Attention
Over the years, drugmakers have sought to raise awareness that attention-deficit hyperactivity disorder, a condition typically diagnosed in childhood, affects young and old alike. Their efforts have only been partially successful.
Read More

Decision Resources Analyst Michael Latwis quoted on Barrons.com

January 25, 2012

Five Big Drugs for 2012
These medications could boost the fortunes of companies like Pfizer, Gilead Sciences and Bristol-Myers Squibb.
Read More

Manhattan Research data quoted in The Wall Street Journal

January 23, 2012

Should Physicians Use Email to Communicate With Patients?
Email has been so commonplace for so long that some people consider it nearly obsolete. But in the health-care profession, its use for communications between doctors and their patients is still controversial.
Read More

Seminar: Competitive Landscape Seminar Series: Oncology

March 8, 2012 to March 8, 2012

This exciting one-day seminar will feature comprehensive analysis of current and future trends in oncology to help you understand and maximize market opportunities. Expert analysts from Decision Resources Group will cover a range of industry and therapeutic-specific issues, addressing the hottest topics in oncology.

Analyst Call: Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments? - On Demand

August 16, 2011 to August 16, 2011

Based on our Pharmacor Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments?

This analyst call was held on August 16, 2011. Contact us to learn how you can purchase this service and access the recorded event.

Click here to view the invite.
Read More

Analyst Call: Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market? - On Demand

July 6, 2011 to July 6, 2011

Based on our Pharmacor Multiple Sclerosis advisory service, Decision Resources is offering an exclusive analyst call entitled Merck Serono Abandons Oral Cladribine: What Impact Will Its Termination Have on the Multiple Sclerosis Drug Market?

This analyst call was held on July 6, 2011. Contact us to learn how you can purchase this service and access the recorded event.

Click here to view the invite.